V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Sarepta Therapeutics Executive Compensation (FY25)

SRPT · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): June 4, 2026
356 figures on this page: 345 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Douglas Ingram was paid $7,840,666 in total compensation as Chief Executive Officer for fiscal 2025, and compared with the $1,978,086 reported for fiscal 2024, Ingram's total was 296.4% higher. Shareholders supported the say-on-pay proposal with 66.9% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025. The disclosed peer group includes ACADIA Pharmaceuticals, Inc., Alkermes plc, Alnylam Pharmaceuticals Inc., argenx SE and BioMarin Pharmaceutical Inc., among others. The 2026 Peer Group names Amicus Therapeutics, Harmony Biosciences and Supernus Pharmaceuticals.
Chief executive, fiscal 2025
◇
Douglas Ingram
Median of the other named officers
$4,233,623
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 4, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Douglas Ingram: $1,978,086 → $7,840,666 (296.4% higher)
Say-on-pay support: 97.1% → 66.9% (30.2 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Sarepta Therapeutics' chief executive and what were they paid?
Douglas Ingram was paid $7,840,666 in total compensation as Chief Executive Officer for fiscal 2025. Compared with the $1,978,086 reported for fiscal 2024, Ingram's total was 296.4% higher.
What was Sarepta Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 66.9% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in Sarepta Therapeutics' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals, Inc., Alkermes plc, Alnylam Pharmaceuticals Inc., argenx SE and BioMarin Pharmaceutical Inc., among others. The 2026 Peer Group names Amicus Therapeutics, Harmony Biosciences and Supernus Pharmaceuticals.
What is Sarepta Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 25:1 for fiscal 2025, against median employee compensation of $308,335.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Douglas Ingram
President and Chief Executive Officer
◇——◇◇—◇◇
William Ciambrone
Executive Vice President, Technical Operations
◇—◇◇◇—◇◇
Louise Rodino-Klapac
Executive Vice President, Head of Research and Development, Chief Scientific Officer
◇—◇◇◇—◇◇
Ian Estepan
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Ryan Brown
Executive Vice President, General Counsel
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Louise Rodino-Klapac
President, Research and Development and Technical Operations
◇—◇◇◇—◇◇
Ian Estepan
President, Chief Operating Officer
◇—◇◇◇—◇◇
Ryan Brown
Executive Vice President, Chief General Counsel
◇—◇◇◇—◇◇
Bilal Arif
Executive Vice President, Chief Technical Operations Officer
◇—◇◇◇—◇◇
Douglas Ingram
Chief Executive Officer
◇———◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ian Estepan
President, Chief Operating Officer
◇—◇◇◇—◇◇
Louise Rodino-Klapac
President, Research and Development and Technical Operations
◇—◇◇◇—◇◇
Dallan Murray
Former Executive Vice President, Chief Customer Officer
◇—◇◇◇—◇◇
Douglas Ingram
Chief Executive Officer
◇◇——◇——◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Douglas Ingram
Chief Executive Officer
◇—◇—◇—◇◇
Louise Rodino-Klapac
President, Research and Development and Technical Operations
◇—◇◇◇—◇◇
Ian Estepan
President, Chief Operating Officer
◇—◇◇◇—◇◇
Cristin Rothfuss
Executive Vice President, General Counsel
◇—◇◇◇—◇◇
Ryan Wong
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Dallan Murray
Former Executive Vice President, Chief Customer Officer
Departed during or after this year
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Cristin L. RothfussPSU◇—◇◇◇——
Cristin L. RothfussRSU◇——◇——◇
Cristin L. RothfussOPTION◇——◇—◇◇
Cristin L. RothfussRSU◇——◇——◇
Cristin L. RothfussPSU◇—◇◇◇——
Dallan MurrayOPTION◇——◇—◇◇
Dallan MurrayPSU◇—◇◇◇——
Dallan MurrayRSU◇——◇——◇
Douglas S. IngramPSU◇—◇◇◇——
Douglas S. IngramPSA◇—◇◇◇——
Douglas S. IngramRSU◇——◇——◇
Ian M. EstepanRSU◇——◇——◇
Ian M. EstepanOPTION◇——◇—◇◇
Ian M. EstepanPSU◇—◇◇◇——
Ian M. EstepanRSU◇——◇——◇
Ian M. EstepanPSU◇—◇◇◇——
Louise Rodino-KlapacPSU◇—◇◇◇——
Louise Rodino-KlapacRSU◇——◇——◇
Louise Rodino-KlapacPSU◇—◇◇◇——
Louise Rodino-KlapacOPTION◇——◇—◇◇
Louise Rodino-KlapacRSU◇——◇——◇
Ryan H. WongRSU◇——◇——◇
Ryan H. WongOPTION◇——◇—◇◇
Ryan H. WongPSU◇—◇◇◇——
Ryan H. WongRSU◇——◇——◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Ryan WongRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Louise Rodino-KlapacRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Cristin RothfussRSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Ian EstepanRSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Douglas IngramPSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
M. Kathleen Behrens
◇◇◇———◇
Richard J. Barry
◇◇◇———◇
Hans Wigzell
◇◇◇———◇
Deirdre Connelly
◇◇◇———◇
Stephen L. Mayo
◇◇◇———◇
Claude Nicaise
◇◇◇———◇
Michael Chambers
◇◇◇———◇
Douglas S. Ingram and Kathryn J. Boor served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals, Inc. ACAD
  • Alkermes plc ALKS
  • Alnylam Pharmaceuticals Inc. ALNY
  • argenx SE ARGX
  • BioMarin Pharmaceutical Inc. BMRN
  • Blueprint Medicines BPMC
  • Exelixis, Inc. EXEL
  • Halozyme Therapeutics, Inc. HALO
  • Incyte Corp. INCY
  • Ionis Pharmaceuticals Inc. IONS
  • Jazz Pharmaceuticals plc JAZZ
  • Neurocrine Biosciences, Inc. NBIX
  • PTC Therapeutics PTCT
  • Repligen Corporation RGEN
  • Ultragenyx Pharmaceutical Inc. RARE
  • United Therapeutics UTHR
  • Vertex Pharmaceuticals VRTX
2026 Peer Group
  • Amicus Therapeutics FOLD
  • Harmony Biosciences HRMY
  • Supernus Pharmaceuticals SUPN

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024June 5, 2025=◇◇◇
2023June 6, 2024=◇◇◇
2022June 8, 2023=◇◇◇
2021June 2, 2022=◇◇◇
2020June 3, 2021=◇◇◇
2019June 4, 2020=◇◇◇
2018June 6, 2019=◇◇◇
2017June 6, 2018=◇◇◇
2016June 6, 2017=◇◇◇
2015June 27, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Sarepta Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Sarepta Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Sarepta Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Sarepta Therapeutics recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Sarepta Therapeutics' disclosed peer group is defensible, who names Sarepta Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
356 figures on this page: 345 cited to the filing that reported them, 11 calculated from figures it prints.
345 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001193125-26-257501
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-177247
    ADVISORY VOTE TO APPROVE NAMED EXECUTIVE OFFICER COMPENSATION (P · CEO Pay Ratio · COMPENSATION COMMITTEE · Compensation Tables · and 2 more sections
  3. 0000950170-25-083131
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-25-058003
    Summary Compensation Table
  5. 0001193125-24-157458
  6. 0000950170-24-047570
    Compensation Tables
  7. 0000950170-23-027276
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000950170-23-014085
    Compensation Tables · Summary Compensation Table
  9. 0000950170-22-011164
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001564590-21-031601
  11. 0001564590-20-028562
  12. 0001564590-19-022044
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001564590-18-015160
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-17-197706
  15. 0001193125-16-634778
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Sarepta Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/SRPT (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Sarepta Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Sarepta Therapeutics discloses

The companies named in SRPT's own disclosed peer group.

ACADIA Pharmaceuticals, Inc.Alkermes plcAlnylam Pharmaceuticals Inc.BioMarin Pharmaceutical Inc.Exelixis, Inc.Halozyme Therapeutics, Inc.Incyte Corp.Ionis Pharmaceuticals Inc.Jazz Pharmaceuticals plcNeurocrine Biosciences, Inc.PTC TherapeuticsRepligen CorporationUltragenyx Pharmaceutical Inc.United TherapeuticsVertex PharmaceuticalsAmicus TherapeuticsSupernus Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy